Funding for this research was provided by:
National Institute of Occupational Safety and Health, Japan (not applicable)
Grant-In-Aid for Scientific Research from the Ministry of Health, Labor and Welfare of Japan (not applicable)
Grant-In-Aid for the Ministry of Education, Culture, Sports, Science and Technology of Japan (not applicable)
Received: 13 February 2020
Accepted: 12 May 2020
First Online: 15 June 2020
Ethics approval and consent to participate
: The Human Ethics Review Committee of University of Occupational & Environmental Health, Japan, reviewed and approved this study, including the collection of peripheral blood samples from HCs and AAV patients. Each subject provided a signed consent form.
: Not applicable.
: S. Nakayamada has received speaking fees from Bristol-Myers, Pfizer, Chugai, Astellas, Sanofi, GlaxoSmithKline, and Asahi-kasei and has received research grants from Mitsubishi-Tanabe, Novartis, and MSD. S. Kubo has received speaking fees from Bristol-Myers. Y. Tanaka has received consulting fees, speaking fees, and/or honoraria from Abbvie, Daiichi-Sankyo, Chugai, Takeda, Mitsubishi-Tanabe, Bristol-Myers, Astellas, Eisai, Janssen, Pfizer, Asahi-kasei, Eli Lilly, GlaxoSmithKline, UCB, Teijin, MSD, and Santen and received research grants from Mitsubishi-Tanabe, Takeda, Chugai, Astellas, Eisai, Taisho-Toyama, Kyowa-Kirin, Abbvie, and Bristol-Myers. All other authors declare no conflict of interest.